<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562419</url>
  </required_header>
  <id_info>
    <org_study_id>CT-322.002</org_study_id>
    <nct_id>NCT00562419</nct_id>
  </id_info>
  <brief_title>CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan</brief_title>
  <official_title>Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adnexus, A Bristol-Myers Squibb R&amp;D Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adnexus, A Bristol-Myers Squibb R&amp;D Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to&#xD;
      the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      CT-322 together with irinotecan may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of&#xD;
      CT-322 when given alone and in combination with irinotecan to patients with glioblastoma&#xD;
      multiforme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CT-322 when administered alone or in combination with irinotecan hydrochloride (Part 1)</measure>
    <time_frame>15 ± 5 days post the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival at 6 months (Part 2)</measure>
    <time_frame>Measured upon initiation of cycles 2, 3, 5, 7, 9, 11, and end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the plasma pharmacokinetics of CT-322 (Cmax, Tmax, AUC, T-HALF) derived from plasma concentration vs time for CT-322 given alone and in combination with irinotecan</measure>
    <time_frame>Part 1: cycle 1, days 1-3, day 5 or 6, days 8, 15, and 22; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. Part 2: cycle 1, days 1, 8, 15, and 22; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the presence of anti CT-322 antibodies</measure>
    <time_frame>Part 1: cycle 1, days 1 and 15; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. Part 2: cycle 1, days 1 and 15; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the biological activity of CT-322 as measured by plasma biological markers and neuroimaging</measure>
    <time_frame>Part 1: cycle 1, days 1, 2, 8, 15 and 22; cycles 2-4, 6, 9, and 12, day 1; EOS visit. Part 2: cycle 1, days 1, 8, 15 and 22; cycles 2-4, 6, 9, and 12 EOS visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Recurrent Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-322</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-322 and irinotecan hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-322</intervention_name>
    <description>IV solution, weekly</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>IV solution, biweekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS&#xD;
&#xD;
          -  Histologically confirmed diagnosis of recurrent/progressive GBM presenting in first,&#xD;
             second, or third relapse (progression following anti-cancer therapy other than&#xD;
             surgery)&#xD;
&#xD;
          -  Bidimensionally measurable recurrent or residual primary disease on contrast-enhanced&#xD;
             MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS&#xD;
&#xD;
        Age:&#xD;
&#xD;
        • 18 and over&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  ANC ≥ 1,500/mL&#xD;
&#xD;
          -  Platelets ≥ 100,000/mL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 x ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
        Coagulation:&#xD;
&#xD;
        • INR &lt; 1.5 or PT within normal limits; and PTT within normal limits&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        Creatinine ≤ 1.5 x ULN; Urine protein/creatinine ratio ≤ 1&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  2-dimensional echocardiogram or cardiac multigated acquisition (MUGA) scan&#xD;
             demonstrating left ventricular ejection fraction within the institutional normal&#xD;
             range.&#xD;
&#xD;
          -  No coronary artery bypass graft, angioplasty, vascular stenting, myocardial&#xD;
             infarction, unstable angina, congestive heart failure within the preceding 12 months.&#xD;
&#xD;
          -  No thrombotic or embolic cerebrovascular accident, including transient ischemic&#xD;
             attacks within the past 12 months and no conditions that would not permit the safe&#xD;
             discontinuation of specified anti-platelet medications&#xD;
&#xD;
          -  No intraparenchymal CNS hemorrhage, except for Grade 1 intraparenchymal hemorrhage in&#xD;
             the immediate post-operative period or Grade 1 intraparenchymal hemorrhage that has&#xD;
             been stable or improved&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
        • Not known to have human immunodeficiency virus infection (HIV) or active hepatitis B or C&#xD;
        virus infection&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Negative pregnancy test within 72 hours prior to drug administration&#xD;
&#xD;
          -  Not pregnant or breast feeding&#xD;
&#xD;
          -  Fertile patients must agree to use effective methods of birth control and must agree&#xD;
             to do so until at least 4 weeks after the last dose of drug administration&#xD;
&#xD;
          -  No serious non-healing wound, ulcer or bone fracture or recent significant traumatic&#xD;
             injury (within 4 weeks)&#xD;
&#xD;
          -  Have ability to understand and sign an informed consent document&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures&#xD;
&#xD;
          -  No other malignancy within the past 3 years, except for basal cell skin cancer,&#xD;
             cervical carcinoma in situ, or other primary malignancy that is not currently&#xD;
             clinically significant or does not require active intervention&#xD;
&#xD;
          -  No prior grade 3 or greater toxicity to irinotecan&#xD;
&#xD;
          -  No other severe, acute, or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that could increase the risks associated with study participation or study&#xD;
             drug administration or could interfere with the interpretation of the study results&#xD;
             and would make the patient inappropriate for study entry&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks between prior biological or immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas),&#xD;
             unless there is unequivocal evidence of tumor progression&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
        • At least 12 weeks from completion of standard, daily radiotherapy and recovered, unless&#xD;
        any of the following occurs:&#xD;
&#xD;
          -  New area of enhancement on MRI that is outside the radiotherapy field&#xD;
&#xD;
          -  Biopsy-proven recurrent tumor&#xD;
&#xD;
          -  Radiographic evidence of progressive tumor on 2 consecutive scans taken ≥ 4 weeks&#xD;
             apart&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since major surgery, open biopsy or significant traumatic injury and&#xD;
             recovered&#xD;
&#xD;
          -  At least 1 week since other prior biopsy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not concurrently enrolled in another therapeutic clinical trial involving ongoing&#xD;
             therapy&#xD;
&#xD;
          -  No prior treatment with VEGF or VEGFR inhibitors or vascular targeting/disrupting&#xD;
             agents&#xD;
&#xD;
          -  No prior CT-322 therapy&#xD;
&#xD;
          -  No prior failure of irinotecan therapy&#xD;
&#xD;
          -  No prior treatment with stereotactic radiosurgery, brachytherapy, or a surgically&#xD;
             created resection cavity to support other anatomically localized therapies&#xD;
&#xD;
          -  No severe or uncontrolled medical disease (uncontrolled diabetes, hypertension,&#xD;
             serious infection &gt; CTCAE grade 2, significant bleeding or platelet dysfunction,&#xD;
             gastrointestinal bleed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virgina</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director, Adnexus, A Bristol-Myers Squibb R&amp;D Company</name_title>
    <organization>Adnexus, A Bristol-Myers Squibb R&amp;D Company</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

